Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721260 · ClinicalTrials.gov registry record
Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)
A clinical trial of Bladder Cancer, sponsored by University of Kansas Medical Center.
- Recruiting
- Registry status
- 30
- Enrollment target
- 2
- Study locations
NCT06721260: Recruiting study of Bladder Cancer, sponsored by University of Kansas Medical Center.
NCT06721260 is a study of Bladder Cancer that is actively recruiting participants, run by University of Kansas Medical Center. The registered enrollment target is 30 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06721260, a study of Bladder Cancer, is actively recruiting participants, sponsored by University of Kansas Medical Center.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care. The study team found in a previous study that resting energy can be different than what estimates show. Patients with bladder cancer are known to suffer a decline in physical resilience over time. Monitoring patients to understand these changes better could help design future treatments with these vulnerabilities in mind.
Primary Outcome
Resting Energy Expenditure (REE) will be measured using indirect calorimetry before and after chemotherapy and radical cystectomy and will be associated with clinical outcomes.
Conditions Studied
Study Locations (2)
Kansas
- University of Kansas Medical Center - Kansas City
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2027-06 |
What NCT06721260 shows while recruiting
NCT06721260 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06721260 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT06721260 about?
NCT06721260 is a clinical study titled "Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)". This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care. The study team found in a previous study that resting energy can be different than what estimates show. Patients with bladder cancer...
What is the current status of trial NCT06721260?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-01-21. Estimated completion is 2027-06.
What conditions does trial NCT06721260 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT06721260?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721260 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06721260's enrollment target sits among peer trials
30 135th of 175 higher than 37 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI